source
- Lilly’s retatrutide creeps closer to market for sleep apneaExpectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of even…Endpoints · 31m ago↗ source
- FDA approves Hibsago, first antisense therapy for chronic hepatitis BThe U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…